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Purpose/Objective: To evaluate the therapeutic outcomes of 
short course neoadjuvant and concurrent androgen-
deprivation therapy (ADT) and intensity-modulated radiation 
therapy (IMRT) with fiducial gold markers for intermediate 
and high-risk prostate cancer.  
Materials and Methods: This is a retrospective study of 325 
patients with intermediate or high-risk prostate cancer 
according to the National Comprehensive Cancer Network 
guidelines who underwent ADT(neoadjuvant :4-8months 
,concurrent:2months) and IMRT (76 Gy) with gold marker 
implantation between 2001 and 2010. 
Results: Five-year distant metastasis-free survival was 
significantly lower for super high-risk patients compared with 
intermediate and high-risk patients (82.6% vs. 99.4% and 
96.5%, respectively; p < 0.01). The 5-year biochemical 
relapse-free survival rates significantly declined with 
increasing prostate cancer risk (p < 0.01) and were 95.9%, 
87.2%, and 73.1% for the intermediate-risk, high-risk, and 
super high-risk patients, respectively. With multivariate 
analysis identified high pretreatment PSA level (³ 20 ng/ml) 
and Gleason sum ³ 8 as significant risk factors for recurrence 
and the duration of ADT was not statistically significant 
defference in BRFS in each risk group. Acute genitourinary 
and gastrointestinal toxicity grade ≥3 were not observed in 
any of the patients. Late grade 3 genitourinary toxicity 
occurred in 0.3% of patients. 
Conclusions: Short course ADT with 76-Gy IMRT using fiducial 
gold markers resulted in good therapeutic outcomes with few 
serious complications in patients with intermediate and high-
risk prostate cancer except super high risk group. More 
intensive therapy might be necessary for super high risk 
group. 
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Purpose/Objective: Previous clinical phase I/II trials have 
confirmed that radiotherapy (RT) in combination with 
regional hyperthermia (HT) is promising and feasible without 
severe toxicity in patients with prostate cancer. We 
hypothesized the positive relationships between the clinical 
outcomes and thermal parameters. The purpose of our study 
was to assess the efficacy of RT combined with regional HT 
and the potential contribution of regional HT with higher 
thermal parameters to the clinical outcomes in patients with 
high-risk prostate cancer. 
Materials and Methods: According to our institution’s 
treatment protocol, HT was combined with RT to improve the 
clinical outcomes in selected patients with high-risk prostate 
cancer. Eighty-two patients treated with RT plus HT and 64 
patients treated with RT alone were retrospectively 
analyzed. The primary reasons for non-indication of HT were 
as follows: obesity: n=20, an advanced age: n=12, patient 
refusal: n=8, cardiac disease: n=6, and others: n=18. All 
patients were treated with 3D-CRT in 70 Gy at 35 fractions 
with the exception of nine patients. HT using an 8-MHz 
radiofrequency-capacitive heating device was applied 
immediately after RT once or twice a week. The median 
duration of heating was 50 minutes (range, 30-50) in one 
heating session. The median number of heating sessions 
ranged from two to six (median 5). All patients initially 
underwent neoadjuvant androgen deprivation therapy (ADT) 
(median, 9 months); adjuvant ADT was continued in 20 
patients after the completion of RT (median, 5 months). 
Univariate and multivariate analyses were performed using 
several factors including thermal parameters to identify 
prognostic factors for the biochemical disease-free survival 
(bDFS). 
Results: The median follow-up duration was 61 months. The 
five-year bDFS rate in 82 patients treated with RT plus HT 
was 78%, while that in 64 patients treated with RT alone was 
72%; the difference was not significant. Among 75 patients 
treated with RT plus HT with intra-rectal temperature 
measurements, higher thermal parameters were significant 
prognostic factors for the bDFS in the univariate analyses. A 
higher thermal parameter of CEM43?T90 (≥ 1 minute) and a T 
stage of T1-2 were significant prognostic factors according to 
the multivariate analysis. The five-year bDFS rates for the 40 
patients with a higher CEM43?T90 and 64 patients treated 
with RT alone were significantly different, whereas those for 
the 35 patients with a lower CEM43?T90 and 64 patients 
treated with RT alone were not. A significant negative 
correlations was observed between the CEM43?T90 and the 
thickness of the maximum ventral subcutaneous fat in the 
pelvic region. 
Conclusions: The addition of HT with higher thermal 
parameters to RT may improve the bDFS in patients with 
high-risk prostate cancer. The findings also indicate the 
importance of the careful selection of treatable patients with 
higher thermal parameters.  
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Purpose/Objective: We report the toxicity and clinical 
outcome for prostate dose-painting radiotherapy with 
moderate hypo-fractionation (dose to prostate 60Gy in 20 
fractions, integrated boost dose 66-68Gy in 20 fractions); 
